These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25572273)

  • 1. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Abolghasmi R; Taziki O
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
    Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
    J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
    Lazich I; Bakris GL
    Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
    Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension in chronic kidney disease-treatment standard 2023.
    Georgianos PI; Agarwal R
    Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.